10x Genomics, Inc. (TXG) stock analysis

In our weekly check, 10x Genomics, Inc. is graded D (A to F). Of 21 checks on debt, profit, cash flow and trend: 11 pass, warnings: 1, red flags: 9.

About 10x Genomics, Inc.

10x Genomics, Inc. is a Healthcare company (Health Information Services) based in the United States, listed on NASDAQ as TXG.

What our checks show for TXG

Red flags

Warning signs

Strengths

Next earnings report: 2027-02-11

Similar companies

IMVT · ORKA · KOD · TWST · ARWR · AXSM

Questions

What grade does 10x Genomics, Inc. (TXG) have?

In our weekly check, 10x Genomics, Inc. is graded D (A to F). Of 21 checks on debt, profit, cash flow and trend: 11 pass, warnings: 1, red flags: 9. The grade is a risk check, not a buy or sell recommendation.

What are the main risks of TXG stock?

This week's biggest flags for 10x Genomics, Inc.: Gross margin falling, Weak EPS forecast, Weak EPS growth. In total 10 of 21 checks show a warning or a red flag.

What does 10x Genomics, Inc. do?

10x Genomics, Inc. is a Healthcare company (Health Information Services) based in the United States, listed on NASDAQ as TXG.

When does 10x Genomics, Inc. report earnings next?

The next earnings report is expected on 2027-02-11. We re-run the checks every week, so the grade can change after it.

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-11-14

Open the full analysis